AKR1C3 Enzyme Prodrug
OBI-3424 is a first-in-class novel prodrug that can selectively act on a variety of cancers with overexpression of Aldo-keto reductase family 1 member C3 (AKR1C3). OBI-3424 has been granted Orphan Drug Designation (ODD) for the treatment of hepatocellular carcinoma (HCC) and acute lymphocytic leukemia (ALL).
The Phase I/II dose escalation study and evaluation of the dose limiting toxicity is being conducted at the University of Texas MD Anderson Cancer Center and Ohio University, The James Cancer Hospital and Solove Research Institute.
In May 2020, OBI published an abstract at the American Society of Clinical Oncology (ASCO) virtual annual meeting, presenting the OBI-3424 Phase I/II clinical trial process and preliminary data.
OBI-3424 cohort expansion phase will use an immunohistochemistry (IHC) method to screen patients with high AKR1C3 expression as recruitment population.
AACR-NCI-EORTC 2017 International Conference on Molecular Targets and Cancer Therapeutics, Philadelphia, PA.(USA), Oct. 26-30, 2017
“The AKR1C3-Activated Prodrug OBI-3424 Exerts Profound In Vivo Efficacy Against Preclinical Models of T-Cell Acute Lymphoblastic Leukemia (T-ALL); a Pediatric Preclinical Testing Consortium Study”, presented by Prof. Richard B. Lock, PhD.
AACR 2016 Annual Meeting, New Orleans, LA (USA), April 16-20, 2016
“Broad In Vitro and In Vivo Antitumor Activity of TH-3424: Preclinical Rationale for a Highly Selective AKR1C3 Prodrug for Treating Cancer”, presented by Dr. Jianxin Duan, PhD.